Singapore markets close in 5 hours 59 minutes

SeaStar Medical Holding Corporation (ICU)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.4100+0.0237 (+6.14%)
At close: 04:00PM EDT
0.4000 -0.01 (-2.44%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3863
Open0.3860
Bid0.4041 x 400
Ask0.4810 x 200
Day's range0.3661 - 0.4100
52-week range0.1620 - 1.7170
Volume816,976
Avg. volume3,871,412
Market cap30.512M
Beta (5Y monthly)-0.93
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    SeaStar Medical Reports First Quarter 2024 Financial Results and Provides a Business Update

    DENVER, May 14, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three months ended March 31, 2024 and provides a business update. “As we guided in late February, we expect initial sales in the coming weeks of Quelimmune™ Pediatric, which is approved for the tre

  • GlobeNewswire

    SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

    DENVER, April 30, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the National Institutes of Health’s (NIH) National Heart, Lung, and Blood Institute has awarded a $3.6 million grant for a clinical trial to evaluate the Selective Cytopheretic Device Adult (SCD-ADULT, a member of the Company’s Quelimmune™ product family) as a bridgin

  • GlobeNewswire

    SeaStar Medical Reports 2023 Financial Results and Provides a Business Update

    DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the 12 months ended December 31, 2023 and provides a business update. “It was exceptionally exciting to receive our first FDA approval for Quelimmune™, which is now available for treating critically